Business Context and Reporting Period
This Form 8-K filing by Veritone, Inc. (Delaware) covers events occurring on May 17, 2017, coinciding with the closing of the Company's Initial Public Offering (IPO). The report details the issuance of equity securities, changes to the Board of Directors, and amendments to the Company's governing documents.
Key Financial Metrics and Capital Events
- Warrant Exercise Proceeds: Acacia Research Corporation exercised its Primary Warrant, purchasing 2,150,335 shares of Common Stock at $13.6088 per share, generating approximately $29.3 million in net proceeds.
- Debt Conversion: Upon IPO completion, $8.0 million in principal outstanding and all accrued interest under secured convertible bridge notes held by Veritone LOC I, LLC and Acacia were converted into 590,878 shares of Common Stock at a conversion price of $13.6088 per share.
- Stock Authorization: The Restated Certificate of Incorporation authorizes 75,000,000 shares of common stock and 1,000,000 shares of undesignated preferred stock.
Note: This filing does not provide revenue, profit, cash flow, or margin data as it is a current report on specific corporate events rather than a periodic financial statement.
Material Changes and Corporate Governance
Board of Directors Changes
Effective May 17, 2017, the Board size was increased to nine authorized directors. Three new directors were appointed:
- Jeff Gehl: Nominated by Major Stockholders.
- Edward J. Treska: Nominated by Acacia Research Corporation.
- Frank E. Walsh, III: Nominated by Acacia Research Corporation.
Under a Voting Agreement, Acacia retains the right to nominate three directors and Major Stockholders retain the right to nominate six directors for a 24-month period following the IPO.
Compensatory Arrangements
Each of the three newly appointed directors received 5,000 restricted stock units (RSUs) under the 2017 Stock Incentive Plan. These RSUs vest upon the earlier of one year of service or the day preceding the first regular annual stockholders meeting after the grant date.
Amendments to Governing Documents
The Company filed a Third Amended and Restated Certificate of Incorporation and adopted amended and restated bylaws. Key provisions include:
- Establishment of a classified board of directors with three classes.
- Requirement of a 66 2/3% supermajority vote to amend bylaws, repeal the Restated Certificate, or remove directors with cause.
- Prohibition of stockholder action by written consent; all actions must occur at a meeting.
- Designation of the Court of Chancery of the State of Delaware as the exclusive forum for certain legal actions.
- Elimination of references to previously existing preferred stock series.
Outlook and Risks
The filing confirms that Common Stock commenced trading on the NASDAQ Global Market on May 15, 2017. The issuance of shares via warrant exercise and debt conversion was determined to be exempt from registration under Section 4(2) of the Securities Act and Rule 506 of Regulation D. No specific forward-looking guidance or risk factors beyond standard corporate governance changes are detailed in this specific text.
Investor Verification Checklist
- Verify the total number of shares outstanding post-IPO, including the 2,150,335 shares from the warrant exercise and 590,878 shares from debt conversion.
- Review the Voting Agreement to understand the control dynamics between Acacia Research Corporation and Major Stockholders over the next 24 months.
- Confirm the vesting schedule and potential dilution impact of the 15,000 total RSUs granted to new directors.
- Examine the Restated Certificate of Incorporation (Exhibit 3.1) for specific anti-takeover provisions, such as the classified board and supermajority voting requirements.
- Check the press release (Exhibit 99.1) for the final IPO pricing and total capital raised, as this filing only details the warrant exercise proceeds.